ArticleClinical and translational radiation oncology2026
Normal tissue complication probability modeling of radiation-induced neck fibrosis in head and neck Cancer survivors: a patient-reported outcome-based analysis.
Article in Clinical and translational radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Skin and soft tissue fibrosis of the neck is a common late toxicity after head and neck radiotherapy (Muehlebach et al., 2025; Ramia et al., 2022; Strojan et al., 2017 [1], [2], [3]), yet no dedicated patient-reported outcome (PRO) instrument exists to capture its specific functional and quality-of-life (QOL) impact. Renslo et al. (2024), Shaw et al. (2016) [4], [5], [6] This study evaluates a fibrosis-directed PRO adapted from scleroderma research and explores dosimetric correlates and normal tissue complication probability (NTCP) relationships for neck fibrosis. [7]. Materials and Methods: In an IRB-approved prospective trial, 95 patients in remission after curative-intent head and neck radiotherapy completed the EORTC QLQ-C30, QLQ-H&N43, and the 22-item Scleroderma Skin Patient-Reported Outcome (SSPRO) instrument. [7], [8], [9] Neck organs at risk (OARs) constituting skin, subcutaneous tissue, and sternocleidomastoid (SCM) muscle were retrospectively contoured; dose-volume metrics are analyzed using Lyman-Kutcher-Burman (LKB) NTCP modeling. Results: All 95 patients completed SSPRO, QLQ-C30, and QLQ-H&N43. Correlation analyses showed moderate-to-strong associations between SSPRO and established QOL instruments. SSPRO total scores categorized using pre-specified thresholds (mild 0-20, moderate 21-40, severe ≥41) showed 64.4% mild, 20.0% moderate, and 15.6% severe fibrosis-related symptom burden. In non-surgical patients, higher mean dose and selected V_x metrics to skin, SCM, and subcutaneous tissue were positively associated with worsening SSPRO scores, whereas no robust dose-response was seen in surgically treated patients. Conclusions: SSPRO captures neck fibrosis-related QOL impairment that is incompletely reflected by standard head and neck QOL instruments. PRO-anchored NTCP modeling suggests that dose to skin, SCM, and subcutaneous tissue predicts fibrosis-related PRO deterioration in non-surgical patients. Eisbruch et al. (1999, 2004), Murdoch-Kinch et al. (2008), Nutting et al. (2011) [10], [11], [12], [13], [14] Exploratory replanning analyses suggest these candidate constraints may be technically achievable and warrant prospective validation before clinical implementation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.